Navigation Links
Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients

he 24-month follow-up of continued COPAXONE(R) therapy, primary outcomes were safety and tolerability. Secondary outcomes included changes from baseline to 24 months in Gd-enhancing lesions, relapses and EDSS.

Thirty patients entered the extension study. Analyses at 15 months indicated a 70 percent reduction in Gd-enhancing lesions in the mitoxantrone-COPAXONE(R) group vs COPAXONE(R) group (risk ratio=0.30, 95 percent CI (0.11-0.86), p=0.0147). These effects appeared to be sustained.

The analysis, Reductions in Gd Enhancing Lesions Observed with Glatiramer Acetate Following a Brief and Low Dose Course of Mitoxantrone in Patients with Relapsing Remitting Multiple Sclerosis (RRMS) Are Paralleled by Favorable Effects on MRI Markers of Disease Burden and Black Hole Evolution, evaluated whether effects on MRI markers of disease burden and tissue damage corroborate the beneficial effects on disease activity observed 15 months after initiating COPAXONE(R) therapy with a brief, low dose induction with mitoxantrone.

The abstract is accessible online at: http://www.abstracts2view.com/aan2007boston/view.php?nu=AAN07L_P06.104 &terms. (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.)

This analysis compared patients who were randomized to receive either three months of induction treatment with mitoxantrone followed by COPAXONE(R) for 12 months (n=21) or COPAXONE(R) alone (n=19) for 15 months.

The further MRI analyses showed that the reductions in Gd-enhancing lesions and relapse activity seen at 15 months were accompanied by significant differences favoring the mitoxantrone-COPAXONE(R) group in the change from baseline in the volume of T2-weighted lesions (p=0.0139), the volume of T1-weighted lesions (p=0.0303) and the proportion of Gd-enhancing lesions that evolved into chronic black holes at month 15 (p=0.0023).

The analysis, "Tracking In Vivo
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis
2. Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis
3. Data on Higher Dose of Copaxone and Data Showing Copaxone is Most Cost Effective
4. Data Published in Neurology Showed That Higher Dose of Copaxone Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS)
5. First Pharmacoeconomic Analysis with Long-Term Data Showed Copaxone Was More Cost-Effective Than Interferon Beta Therapies for Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)
6. Point of Care Strep Tests Speed Treatment, Lower Costs
7. Rapid HIV Testing Increases Possibility of Treatment
8. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
9. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
Post Your Comments:
(Date:7/30/2014)... Advanced Photonix ® (NYSE MKT: API) will ... results on Monday, August 11, 2014. A press release announcing ... the market and the Company will host a live audio ... on the same day. Participating in the call ... Rob Risser (COO and Director), and Jeff Anderson ...
(Date:7/30/2014)... July 30, 2014  Unilife Corporation ("Unilife" or ... developer and supplier of injectable drug delivery systems, ... capacity, R&D, and facilities in response to increasing ... products and services. During the fourth quarter of ... million in capital expenditures and R&D above normal ...
(Date:7/30/2014)... 30, 2014 /PRNewswire-iReach/ -- Transluminal Technologies LLC, a ... company, has announced today that they have received ... Closure Device. Velox CD™ provides a safe and ... femoral procedures. The single size velox CD™ is ... from 5F to 8F.  Velox CD™ ...
Breaking Medicine Technology:Advanced Photonix to Webcast Fiscal 2015 First Quarter Earnings 2Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 2Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 3Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 4Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 5Transluminal Technologies receives CE Mark approval for velox CD(TM) vascular closure device 2
... Calif., March 7, 2012  Isis Pharmaceuticals, Inc. (NASDAQ: ... 1 study of ISIS-STAT3Rx, a Generation 2.5 antisense drug ... of signal transducer and activator of transcription 3 (STAT3). ... cancers, ISIS-STAT3Rx has the potential to be broadly useful ...
... March 7, 2012  Solta Medical, Inc. (NASDAQ: ... market, today provided an update on the launch of ... approved by the FDA. A majority ... comprised of leading plastic surgeons and dermatologists, who received ...
Cached Medicine Technology:Isis Initiates Phase 1 Study in Patients With Cancer With the First Generation 2.5 Antisense Drug, ISIS-STAT3Rx 2Isis Initiates Phase 1 Study in Patients With Cancer With the First Generation 2.5 Antisense Drug, ISIS-STAT3Rx 3Isis Initiates Phase 1 Study in Patients With Cancer With the First Generation 2.5 Antisense Drug, ISIS-STAT3Rx 4Solta Medical Provides Update on Liposonix Launch 2Solta Medical Provides Update on Liposonix Launch 3Solta Medical Provides Update on Liposonix Launch 4
(Date:7/31/2014)... (PRWEB) July 31, 2014 Cheerag ... experienced, sub-specialty trained neurosurgeons at the Saint Luke’s ... Spine Program and director of spine surgery. He comes ... Wash. , “Dr. Upadhyaya has been recognized for his ... complex spine issues. His addition to the Saint Luke’s ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 What’s ... practice provider? Community Health Center of Snohomish answers ... Pediatricians vs. Family Doctors ”. Many adults can ... available to them. Community Health Center hopes to ... and differences between the two. , To ...
(Date:7/31/2014)... Bellava MedAesthetics is proud to introduce ... surgeon! , Dr. Kim has more than a ... the look of their dreams. He focuses on natural ... augmentation (including Gummy Bear implants ), laser liposuction, ... Brazilian butt lift), abdominoplasty (tummy tuck), rhinoplasty, blepharoplasty (eyelid ...
(Date:7/31/2014)... 2014 When it comes to aesthetics ... and improve. As such, Natalie Sharp's Pure Vitality ... for a new, more focused direction and to provide ... patients! , Pure Vitality Rx is Oyster Bay's premier ... wide variety of services primarily dedicated to women. Services ...
(Date:7/31/2014)... Boston, MA (PRWEB) July 31, 2014 Many ... fight for the weak, to correct injustices, and preserve the ... - action that can be lauded as crusading and exemplary ... the lawyer takes on corruption whose seed might be planted ... a fury and the ultimate punishment for an attorney - ...
Breaking Medicine News(10 mins):Health News:Saint Luke’s Marion Bloch Neuroscience Institute welcomes Cheerag D. Upadhyaya, M.D., as director of Spine Program 2Health News:Saint Luke’s Marion Bloch Neuroscience Institute welcomes Cheerag D. Upadhyaya, M.D., as director of Spine Program 3Health News:Saint Luke’s Marion Bloch Neuroscience Institute welcomes Cheerag D. Upadhyaya, M.D., as director of Spine Program 4Health News:Community Health Center of Snohomish County Reveals the Differences Between Pediatricians and Family Practice Providers 2Health News:Bellava MedAesthetics Welcomes Dr. Chang Soo Kim as Its New Westchester Plastic Surgeon 2Health News:Natalie Sharp's Pure Vitality Rx Upgrade - Partnership With Shangri-La Spa and Website Facelift! 2Health News:Supreme Court Press Petition of the Month for July 2014: Shutting Down Inconvenient Lawyers By Disbarment or Suspension 2Health News:Supreme Court Press Petition of the Month for July 2014: Shutting Down Inconvenient Lawyers By Disbarment or Suspension 3
... Carolina at Chapel Hill researchers published a study that found ... to have Parkinson,s disease than people with high LDL levels. ... whether low LDL (low-density lipoprotein) levels were present in study ... developed low LDL levels after being diagnosed. , Now a ...
... 4, 2008 Smart Balance,Inc. (Nasdaq: SMBL ) ... been named to the position of vice president, business,development. ... vice president,general manager, Midwest. Brett Meltzer has been named ... three are new employees of the,Company., "I am ...
... raises prospect of new treatment for tick-borne diseases in ... injection of a long-acting version of the antibiotic doxycycline ... Lyme disease or anaplasmosis, new animal research reveals. , ... raises hope for developing a safer and more effective ...
... & Research (NTMir), a,Miami, Florida based not-for-profit organization, ... been awarded to the Research,Institute of the McGill ... Genome Sequence of Mycobacterium avium intracellulare.", The ... NTMir in its innovative,research initiative, Rapid Information Pilot ...
... Business and,Disrupt Services to as Many as a Half ... April 4, 2008 A new Medicare,bidding program for ... Cincinnati and Cleveland, Ohio areas on July 1, 2008,will ... likely disrupt,services for many of the 540,000 seniors and ...
... A promising vaccine being tested for Alzheimer,s disease does ... plaques from the brain -- but it does not ... according to a University of California, Irvine study. , ... Alzheimer,s disease -- beta-amyloid plaques -- by itself may ...
Cached Medicine News:Health News:Pieces coming together in Parkinson's, cholesterol puzzle 2Health News:Smart Balance Announces Sales Organization Appointments 2Health News:Smart Balance Announces Sales Organization Appointments 3Health News:Injectable Antibiotic Protects Against Lyme Disease in Mice 2Health News:Injectable Antibiotic Protects Against Lyme Disease in Mice 3Health News:Errors Plague Medicare 'Competitive Bidding' Program in Ohio, Says American Association for Homecare 2Health News:Errors Plague Medicare 'Competitive Bidding' Program in Ohio, Says American Association for Homecare 3Health News:Errors Plague Medicare 'Competitive Bidding' Program in Ohio, Says American Association for Homecare 4Health News:Alzheimer's vaccine clears plaque but has little effect on learning and memory impairment 2
Printed with large 20/200 E on one side and a series of five 20/20 tumbling Es on the other- calibrated to a 20 ft. distance. May be used to test and train peripheral awareness....
... 2/25 is an economically priced 2-channel ... and research use in the fields ... neurophysiology, biology, zoology, biochemistry and biomedical ... ADInstruments signal conditioners and transducers. Two ...
... The PowerLab/4SP is a high-performance data ... of research applications including human and animal ... biomedical engineering. The unit is capable of ... speeds (up to 200 000 samples per ...
... Worth 4 Dot with 955R Red/Green ... the presence of binocular vision. Consists ... illuminated discs: two green, one red ... at any distance. Patient wears red/green ...
Medicine Products: